Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091949 · ClinicalTrials.gov registry record · Phase 3
Insulin Resistance Intervention After Stroke Trial
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,876
- Enrollment target
NCT00091949: Completed Phase 3 study, sponsored by Yale University.
NCT00091949 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 3,876 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (402% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091949, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,876 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
Interventions
- DRUG placebo
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,876 participants |
| Start Date | 2005-02 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
What the finished NCT00091949 record still lists
NCT00091949 is an interventional study that assigns participants to a tested intervention. Its 3,876 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (402% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00091949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091949 about?
NCT00091949 is a clinical study titled "Insulin Resistance Intervention After Stroke Trial". The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
What is the current status of trial NCT00091949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,876 participants. The study started on 2005-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00091949?
The interventions under investigation include: placebo (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00091949?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091949's enrollment target sits among peer trials
3,876 65th of 2000 higher than 1,936 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia